Pharmacodynamics of Daptomycin in a Murine Thigh Model of Staphylococcus aureus Infection
暂无分享,去创建一个
Michael H. Miller | George L. Drusano | Arnold Louie | G. Drusano | N. Jumbe | Weiguo Liu | Pamela Kaw | Nelson Jumbe | A. Louie | Weiguo Liu | P. Kaw
[1] E. Bruck,et al. National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.
[2] W. Alborn,et al. Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032 , 1987, Antimicrobial Agents and Chemotherapy.
[3] G. Eliopoulos,et al. In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic , 1986, Antimicrobial Agents and Chemotherapy.
[4] J. Bilello,et al. Impact of dosing schedule upon suppression of a retrovirus in a murine model of AIDS encephalopathy , 1994, Antimicrobial Agents and Chemotherapy.
[5] Y. Fukuchi,et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin , 1997, The Lancet.
[6] I. L. Smith,et al. Role for dual individualization with cefmenoxime. , 1984, The American journal of medicine.
[7] G. Drusano,et al. Daptomycin: a novel agent for Gram-positive infections. , 1999, Expert opinion on investigational drugs.
[8] A. Gerber,et al. Constant infusions vs. intermittent doses of gentamicin against Pseudomonas aeruginosa in vitro. , 1982, The Journal of infectious diseases.
[9] P. Huovinen,et al. In vitro activity of a new cyclic lipopeptide antibiotic, LY146032, against gram-positive clinical bacteria , 1987, Antimicrobial Agents and Chemotherapy.
[10] U. Flückiger,et al. Integration of pharmacokinetics and pharmacodynamics of imipenem in a human-adapted mouse model , 1991, Antimicrobial Agents and Chemotherapy.
[11] G. Drusano. Role of pharmacokinetics in the outcome of infections , 1988, Antimicrobial Agents and Chemotherapy.
[12] G. Drusano,et al. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis , 1993, Antimicrobial Agents and Chemotherapy.
[13] W. Alborn,et al. Daptomycin disrupts membrane potential in growing Staphylococcus aureus , 1991, Antimicrobial Agents and Chemotherapy.
[14] H. Akaike. A new look at the statistical model identification , 1974 .
[15] I. Bakker-Woudenberg,et al. Continuous versus intermittent administration of ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and leukopenic rats , 1986, Antimicrobial Agents and Chemotherapy.
[16] F. Lowy. Staphylococcus aureus infections. , 2009, The New England journal of medicine.
[17] B. Brenner,et al. Glomerular actions of angiotensin II. , 1984, The American journal of medicine.
[18] Mary Jane Ferraro,et al. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .
[19] N. Melchior,et al. In-vitro evaluation of ampicillin/brobactam and comparison with other beta-lactam antibiotics. , 1991, The Journal of antimicrobial chemotherapy.
[20] R. Smith,et al. Comparison of in vitro inhibitory and bactericidal activities of daptomycin (LY 146032) and four reference antibiotics, singly and in combination, against gentamicin-susceptible and high-level-gentamicin-resistant enterococci. , 1993, Chemotherapy.
[21] G. Bodey,et al. A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. , 1979, The American journal of medicine.
[22] W. Craig,et al. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. , 1991, The Journal of antimicrobial chemotherapy.
[23] M. Sachdeva,et al. Effect of protein binding of daptomycin on MIC and antibacterial activity , 1991, Antimicrobial Agents and Chemotherapy.
[24] F. Tenover,et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. , 1997, The Journal of antimicrobial chemotherapy.
[25] W. Craig,et al. Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models. , 1990, Scandinavian journal of infectious diseases. Supplementum.
[26] R. Stern,et al. Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin. , 1983, The Journal of infectious diseases.
[27] J. Turnidge,et al. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. , 1988, The Journal of infectious diseases.
[28] H. Black,et al. Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers , 1992, Antimicrobial Agents and Chemotherapy.
[29] E. Bingen,et al. Bactericidal activity of vancomycin, daptomycin, ampicillin and aminoglycosides against vancomycin-resistant Enterococcus faecium. , 1990, The Journal of antimicrobial chemotherapy.
[30] G L Drusano,et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. , 1998, JAMA.
[31] J A Bilello,et al. Effect of 2',3'-didehydro-3'-deoxythymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose-ranging clinical studies , 1994, Antimicrobial Agents and Chemotherapy.
[32] J. Waitz. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically , 1990 .
[33] Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997. , 1997, MMWR. Morbidity and mortality weekly report.
[34] J J Schentag,et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients , 1993, Antimicrobial Agents and Chemotherapy.
[35] R. Gaynes,et al. An overview of nosocomial infections, including the role of the microbiology laboratory , 1993, Clinical Microbiology Reviews.
[36] R. Moore,et al. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. , 1987, The Journal of infectious diseases.